The U.S. Supreme Court preserved the U.S. Preventative Services Task Force coverage mandate that requires payers to cover certain preventive services at no cost to patients in a 6-3 ruling. That’s ...

China’s National Medical Products Administration (NMPA) has accepted for review Carsgen Therapeutics Holdings Ltd.’s NDA for satricabtagene autoleucel (satri-cel, CT-041), an autologous CAR T ...

An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR) agonist that mimics the effects of ...

Aprea Therapeutics Inc. has announced new preclinical data on APR-1051, the company’s next-generation oral WEE1 inhibitor, in ...

Industry’s reaction to the U.S. FDA’s draft guidance for remote regulatory assessments included a request for more clarity on when the agency would issue a post-assessment report, but the final ...

CDR-Life Inc. has announced CDR-609 as its next clinical candidate. Built on the company’s proprietary M-gager platform, ...

T-cell activity is often suppressed by the immunosuppressive nature of the tumor microenvironment, contributing to the ...

Visceral leishmaniasis is a fatal disease caused by the Leishmania parasite, affecting organs such as the liver and spleen. Visceral leishmaniasis is considered a neglected tropical disease and is ...

Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...

The U.K. National Health Service may or may not deploy transcatheter aortic valve replacement devices as widely as in the U.S., but the National Institute for Health and Care Excellence officially ...

Hemab ApS recently presented preclinical data on its human monoclonal antibody against von Willebrand factor (vWF), HMB-002, for the treatment of von Willebrand disease.